title: Black hairy tongue associated with erlotinib treatment in a patient with advanced lung cancer.
abstract: Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors (EGFRIs). However, no case of black hairy tongue (BHT) associated with EGFRI has been reported. Herein, we report the first case of erlotinib-induced BHT in a 61-year-old man with advanced lung cancer. Considering recent use of EGFRIs worldwide, dermatologists should recognize the possible occurrence of BHT associated with EGFRIs such as erlotinib.
authors.affiliation: Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Korea.
authors.forename: Jin Seob
authors.initials: JS
authors.lastname: Jeong
authors.forename: Ji Yeoun
authors.initials: JY
authors.lastname: Lee
authors.forename: Mi Kyeong
authors.initials: MK
authors.lastname: Kim
authors.forename: Tae Young
authors.initials: TY
authors.lastname: Yoon